Company Reports

ICU Medical delivered 1% revenue growth in the second quarter, although non-GAAP organic revenue and adjusted earnings per share grew 6% and 13%, respectively. The firm lifted its 2026 guidance for adjusted EPS by 9% at the midpoint, and shares rose 5% in after-hours trading on Aug 6.

With roots as a supplier of infusion consumables, ICU Medical enhanced its product mix through the transformative acquisition of Hospira Infusion Systems from Pfizer in 2017 by bringing infusion pumps, a broader consumables offering, and intravenous solutions manufacturing into the fold. The firm has become a more complete provider with the acquisition of Smiths Medical (various IV-related pumps and other medical supplies) in 2022. In our view, ICU’s focus on building a more comprehensive portfolio adds to the long-term stability of its revenue mix thanks to lengthy contracts and a hallmark razor-and-blade model in its systems business. We think unrivaled scale in consumables may help it generate excess returns eventually, though its portfolio has lost differentiation. By expanding the product offering and incorporating pumps into the business mix, ICU Medical aims to enhance the value proposition that it can offer customers by bundling consumables with larger pump-related contracts.

For first-quarter 2026, ICU Medical reported a 12% revenue decline year over year, although organic revenue grew 1%, and the firm expanded gross margin by over 400 basis points versus a year ago. Management also reaffirmed guidance for 2026.

For the fourth quarter, ICU Medical delivered 2% organic revenue growth year over year and expanded gross margin to 38%, up from 36% a year ago. The company provided 2026 guidance featuring an adjusted EPS midpoint of $8.10, which would represent 5.3% growth over 2025.

ICU Medical's third-quarter earnings featured 5% organic revenue growth year over year, and gross margins expanded by nearly 300 basis points, leading management to raise guidance across the board for fiscal 2025. Shares responded sharply, trading up over 10% in afterhours trading on Nov. 6.

With roots as a supplier of infusion consumables, ICU Medical enhanced its product mix through the transformative acquisition of Hospira Infusion Systems from Pfizer in 2017 by bringing infusion pumps, a broader consumables offering, and intravenous solutions manufacturing into the fold. The firm has become a more complete provider with the acquisition of Smiths Medical (various IV-related products and other medical supplies) in 2022. In our view, ICU’s focus on building a more comprehensive portfolio adds to the long-term stability of its revenue mix thanks to lengthy contracts and a hallmark razor-and-blade model in its systems business. We think unrivaled scale in consumables may help it generate excess returns eventually, though its portfolio has lost differentiation. ICU completed a joint venture with Otsuka Pharmaceutical Factory in May 2025, offloading its lower-margin IV solutions business. Management hopes that a refined focus will lead to margin expansion. In infusion systems, although we believe ICU faces an uphill battle in competing with leader Becton Dickson, we believe the space offers an attractive opportunity to exploit high switching costs. In our view, consumables and infusion systems should be the primary growth drivers for ICU.

The US Commerce Department has launched an investigation into the national security impacts of importing personal protective equipment, medical consumables, and medical devices. Various medical technology companies' shares were down by low to mid-single digits in Sept. 25 intraday trading.

ICU Medical's second quarter featured an 8% decline in year-over-year revenue, but gross profits were essentially unchanged, as the company was able to lift its gross margin by 300 basis points. The firm narrowed its guidance ranges, as it gained more clarity on tariffs, too.

Highlighted by strong performance across its segments, no-moat ICU Medical reported excellent first-quarter results. Total revenue grew 10% year over year in constant currency, and adjusted diluted EPS grew 79% year over year to $1.72, or well above FactSet consensus of $1.28. We are maintaining our fair value estimate of $178 and continue to view shares as undervalued.

Over the past week, tariff-related news has created significant volatility in the US market, including in medical services-related firms like managed care organizations, caregivers, and medical suppliers.

In the fourth quarter, ICU Medical turned in 9% constant-currency sales growth and 34% adjusted earnings per share growth, helped by the shortage of IV solutions in the United States after key peer Baxter's manufacturing facility was forced offline by Hurricane Helene in late September.

No-moat ICU Medical’s third-quarter results are in line with our expectations. Total revenue rose by 7% in constant currency to $580 million, maintaining the healthy growth momentum we saw from in the previous quarter. The company also announced a joint venture with Otsuka Pharmaceutical Factory to bolster its intravenous solutions business. Under the joint venture, ICU will provide commercial services and promote new IV solutions products from OPF to North American customers. According to the management, this deal could potentially bring 400-600 basis points of gross margin benefits to ICU upon its completion in 2025. We are encouraged by ICU’s efforts to improve its business mix, and we are raising our fair value estimate to $178 per share from $161 after incorporating the potential margin benefits from this joint venture.

With roots as a supplier of infusion consumables, ICU Medical enhanced its product mix through the transformative acquisition of Hospira Infusion Systems from Pfizer in 2017 by bringing infusion pumps, a broader consumables offering, and intravenous solutions manufacturing into the fold. The firm has become a more complete provider with the acquisition of Smiths Medical (various IV-related products and other medical supplies) in 2022. In our view, ICU’s focus on building a more comprehensive portfolio adds to the long-term stability of its revenue mix thanks to lengthy contracts and a hallmark razor-and-blade model in its systems business. We think unrivaled scale in consumables may help it to generate excess returns eventually, though its portfolio has lost differentiation. In infusion systems, although we believe ICU faces an uphill battle in competing with leader Becton Dickson, we believe the space offers an attractive opportunity to exploit high switching costs. In our view, consumables and infusion systems should be the primary growth drivers for ICU.

Thanks to healthy medical utilization trends, no-moat ICU Medical reported solid second-quarter results and management increased 2024 guidance. Total revenue grew 10% year over year in constant currency to $581 million, which is the strongest quarterly growth following the 2022 Smiths acquisition. We are maintaining our $161 fair value estimate per share and view shares as moderately undervalued.

No-moat ICU Medical’s first-quarter results came slightly below our expectations. Nevertheless, we are maintaining our $161 fair value estimate, as we see steady progress with the company’s quality remediation and integration initiatives. We think the company is on track to fully integrate with Smiths by the end of 2025, which should bring meaningful margin improvement in the long term.

No-moat ICU Medical reported fourth-quarter results in line with our expectations. However, we are trimming our fair value estimate to $161 per share from $177 because of lower-than-expected 2024 guidance from management. ICU’s integration with Smiths Medical is taking longer than our original projection, but we remain optimistic about the potential cost-saving synergies in the long term.

With roots as a supplier of infusion consumables, ICU Medical enhanced its product mix through the transformative acquisition of Hospira Infusion Systems from Pfizer in 2017 by bringing infusion pumps, a broader consumables offering, and intravenous solutions manufacturing into the fold. The firm has become a more complete provider with the acquisition of Smiths Medical (various IV-related products and other medical supplies) in 2022. In our view, ICU’s focus on building a more comprehensive portfolio adds to the long-term stability of its revenue mix thanks to lengthy contracts and a hallmark razor-and-blade model in its systems business. We think unrivaled scale in consumables may help it to generate excess returns eventually, though its portfolio has lost differentiation. In infusion systems, although we believe ICU faces an uphill battle in competing with leader Becton Dickson, we believe the space offers an attractive opportunity to exploit high switching costs.

No-moat ICU Medical’s third-quarter results were largely in line with our expectations. Adjusted total sales declined by 6% year over year in constant currency, but gross margin expanded 100 basis points on an adjusted basis. Management attributed the top-line decline to the weak performance of acquired products from Smiths, and we believe the operational glitches related to the Smiths acquisition are mostly short-term.

No-moat ICU Medical turned in a mixed second quarter with weaker-than-expected sales but strong profits. Negatively for 2023, management suggested that sales would be weaker than previously expected in a couple businesses and narrowed its guidance range for profits mildly below our previous expectations. However, making a slight cut to our 2023 view does not materially change our $177 fair value estimate, and we continue to view ICU shares as about fairly valued.

We are reducing ICU's moat rating to none, down from narrow, largely to account for uncertainty around the firm's economic profitability related to the Smiths acquisition. In conjunction, we have raised our Uncertainty Rating to High from Medium. The moat reduction shortens our modeled length of economic profitability, which brings our fair value estimate to $177 per share, down from $195 previously.